Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Metformin Use and Cardiovascular Events in Patients with Type 2 Diabetes and Chronic Kidney Disease.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA.

Diabetes Obes Metab. 2019 Jan 22. doi: 10.1111/dom.13642. [Epub ahead of print]

PMID:
30672083
3.

Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial.

Lima EG, Charytan DM, Hueb W, de Azevedo DFC, Garzillo CL, Favarato D, Linhares Filho JPP, Martins EB, Batista DV, Rezende PC, Hueb AC, Ramires JAF, Kalil Filho R.

Nephrol Dial Transplant. 2018 Dec 24. doi: 10.1093/ndt/gfy379. [Epub ahead of print]

PMID:
30590726
4.

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).

Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, Cannon CP, Bakris GL; EXAMINE Investigators.

Am J Cardiol. 2019 Feb 1;123(3):382-391. doi: 10.1016/j.amjcard.2018.10.035. Epub 2018 Nov 6.

PMID:
30477800
5.

Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.

Charytan DM, Himmelfarb J, Ikizler TA, Raj DS, Hsu JY, Landis JR, Anderson AH, Hung AM, Mehrotra R, Sharma S, Weiner DE, Williams M, DiCarli M, Skali H, Kimmel PL, Kliger AS, Dember LM; Hemodialysis Novel Therapies Consortium.

Kidney Int. 2018 Nov 22. pii: S0085-2538(18)30641-0. doi: 10.1016/j.kint.2018.08.034. [Epub ahead of print]

PMID:
30473139
6.

Introduction: Cardiovascular Disease in Chronic Kidney Disease.

Charytan DM.

Semin Nephrol. 2018 Nov;38(6):541. doi: 10.1016/j.semnephrol.2018.08.008. No abstract available.

PMID:
30413249
7.

Extracorporeal Stromal Cell Therapy for Subjects With Dialysis-Dependent Acute Kidney Injury.

Miller BLK, Garg P, Bronstein B, LaPointe E, Lin H, Charytan DM, Tilles AW, Parekkadan B.

Kidney Int Rep. 2018 Jun 2;3(5):1119-1127. doi: 10.1016/j.ekir.2018.05.009. eCollection 2018 Sep.

8.

The Authors Reply.

Charytan DM, Roy-Chaudhury P.

Kidney Int. 2018 Aug;94(2):430-431. doi: 10.1016/j.kint.2018.05.012. No abstract available.

PMID:
30031449
9.

End-Stage Renal Disease and Arrhythmic Death.

Weinrauch LA, Charytan DM, D'Elia JA.

JACC Clin Electrophysiol. 2018 Jul;4(7):975-976. doi: 10.1016/j.jacep.2018.04.018. No abstract available.

PMID:
30025702
10.

Echocardiographic parameters and renal outcomes in patients with preserved renal function, and mild- moderate CKD.

Mavrakanas TA, Khattak A, Singh K, Charytan DM.

BMC Nephrol. 2018 Jul 11;19(1):176. doi: 10.1186/s12882-018-0975-5.

11.

Comparative Utilization and Temporal Trends in Cardiac Stress Testing in U.S. Medicare Beneficiaries With and Without Chronic Kidney Disease.

Herzog CA, Natwick T, Li S, Charytan DM.

JACC Cardiovasc Imaging. 2018 Jun 8. pii: S1936-878X(18)30369-3. doi: 10.1016/j.jcmg.2018.04.012. [Epub ahead of print]

PMID:
29909107
12.

Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle.

Roy-Chaudhury P, Tumlin JA, Koplan BA, Costea AI, Kher V, Williamson D, Pokhariyal S, Charytan DM; MiD investigators and committees.

Kidney Int. 2018 Apr;93(4):941-951. doi: 10.1016/j.kint.2017.11.019. Epub 2018 Feb 12.

13.

Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.

Garlo KG, White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DM.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):398-405. doi: 10.2215/CJN.05280517. Epub 2018 Jan 16.

PMID:
29339356
14.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

15.

Early versus late initiation of renal replacement therapy in patients with acute kidney injury: a meta-analysis of randomised clinical trials.

Mavrakanas TA, Aurian-Blajeni DE, Charytan DM.

Swiss Med Wkly. 2017 Oct 12;147:w14507. doi: 10.4414/smw.2017.14507. eCollection 2017.

16.

Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage.

Charytan DM, Skali H, Shah NR, Veeranna V, Cheezum MK, Taqueti VR, Kato T, Bibbo CR, Hainer J, Dorbala S, Blankstein R, Di Carli MF.

Kidney Int. 2018 Feb;93(2):501-509. doi: 10.1016/j.kint.2017.07.025. Epub 2017 Oct 13.

17.

Epidemiology and Natural History of the Cardiorenal Syndromes in a Cohort with Echocardiography.

Mavrakanas TA, Khattak A, Singh K, Charytan DM.

Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1624-1633. doi: 10.2215/CJN.04020417. Epub 2017 Aug 11.

18.

ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, de Zeeuw D, Eckardt KU, McMurray JJV, Claggett B, Lewis EF, Pfeffer MA.

Am J Kidney Dis. 2017 Oct;70(4):522-531. doi: 10.1053/j.ajkd.2017.04.018. Epub 2017 Jun 7.

PMID:
28599901
19.

Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function.

Stanifer JW, Charytan DM, White J, Lokhnygina Y, Cannon CP, Roe MT, Blazing MA.

J Am Soc Nephrol. 2017 Oct;28(10):3034-3043. doi: 10.1681/ASN.2016090957. Epub 2017 May 15.

20.

The Use of a Multidimensional Measure of Dialysis Adequacy-Moving beyond Small Solute Kinetics.

Perl J, Dember LM, Bargman JM, Browne T, Charytan DM, Flythe JE, Hickson LJ, Hung AM, Jadoul M, Lee TC, Meyer KB, Moradi H, Shafi T, Teitelbaum I, Wong LP, Chan CT; American Society of Nephrology Dialysis Advisory Group.

Clin J Am Soc Nephrol. 2017 May 8;12(5):839-847. doi: 10.2215/CJN.08460816. Epub 2017 Mar 17. Review.

21.

A Decision-Making Algorithm for Initiation and Discontinuation of RRT in Severe AKI.

Mendu ML, Ciociolo GR Jr, McLaughlin SR, Graham DA, Ghazinouri R, Parmar S, Grossier A, Rosen R, Laskowski KR, Riella LV, Robinson ES, Charytan DM, Bonventre JV, Greenberg JO, Waikar SS.

Clin J Am Soc Nephrol. 2017 Feb 7;12(2):228-236. doi: 10.2215/CJN.07170716. Epub 2017 Jan 24.

22.

Cardiovascular complications in chronic dialysis patients.

Mavrakanas TA, Charytan DM.

Curr Opin Nephrol Hypertens. 2016 Nov;25(6):536-544. Review.

23.

Spironolactone in Dialysis: What's Old Is New Again.

Charytan DM.

Am J Kidney Dis. 2016 Oct;68(4):512-514. doi: 10.1053/j.ajkd.2016.07.002. No abstract available. Erratum in: Am J Kidney Dis. 2017 Jan;69(1):162.

PMID:
27664475
24.

Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Stable Angina in Advanced CKD: A Decision Analysis.

Khattak A, Mandel EI, Reynolds MR, Charytan DM.

Am J Kidney Dis. 2017 Mar;69(3):350-357. doi: 10.1053/j.ajkd.2016.07.024. Epub 2016 Sep 16.

25.

Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease.

Charytan DM, Desai M, Mathur M, Stern NM, Brooks MM, Krzych LJ, Schuler GC, Kaehler J, Rodriguez-Granillo AM, Hueb W, Reeves BC, Thiele H, Rodriguez AE, Buszman PP, Buszman PE, Maurer R, Winkelmayer WC.

Kidney Int. 2016 Aug;90(2):411-421. doi: 10.1016/j.kint.2016.03.033. Epub 2016 Jun 1. Review. Erratum in: Kidney Int. 2017 Mar;91(3):758.

26.

Arrhythmia and Sudden Death in Hemodialysis Patients: Protocol and Baseline Characteristics of the Monitoring in Dialysis Study.

Charytan DM, Foley R, McCullough PA, Rogers JD, Zimetbaum P, Herzog CA, Tumlin JA; MiD Investigators and Committees.

Clin J Am Soc Nephrol. 2016 Apr 7;11(4):721-34. doi: 10.2215/CJN.09350915. Epub 2016 Jan 13.

27.

Prognostic Value of Coronary Flow Reserve in Patients with Dialysis-Dependent ESRD.

Shah NR, Charytan DM, Murthy VL, Skali Lami H, Veeranna V, Cheezum MK, Taqueti VR, Kato T, Foster CR, Hainer J, Gaber M, Klein J, Dorbala S, Blankstein R, Di Carli MF.

J Am Soc Nephrol. 2016 Jun;27(6):1823-9. doi: 10.1681/ASN.2015030301. Epub 2015 Oct 12.

28.

Association of circulating angiogenesis inhibitors and asymmetric dimethyl arginine with coronary plaque burden.

Charytan DM, Cinelli A, Zeisberg EM.

Fibrogenesis Tissue Repair. 2015 Jul 21;8:13. doi: 10.1186/s13069-015-0029-6. eCollection 2015.

29.

Shades of grey: the conundrum of implantable defibrillators in individuals with advanced CKD.

Khattak A, Charytan DM.

Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1107-9. doi: 10.2215/CJN.05340515. Epub 2015 Jun 25. No abstract available.

30.

Association of activated vitamin D use with myocardial fibrosis and capillary supply: results of an autopsy study.

Charytan DM, Padera RF, Helfand AM, Zeisberg EM.

Ren Fail. 2015 Jul;37(6):1067-9. doi: 10.3109/0886022X.2015.1040704. Epub 2015 May 8. No abstract available.

PMID:
25955707
31.

Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Charytan DM, Lewis EF, Desai AS, Weinrauch LA, Ivanovich P, Toto RD, Claggett B, Liu J, Hartley LH, Finn P, Singh AK, Levey AS, Pfeffer MA, McMurray JJ, Solomon SD.

Am J Kidney Dis. 2015 Sep;66(3):429-40. doi: 10.1053/j.ajkd.2015.02.324. Epub 2015 Apr 29.

32.

Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia.

Charytan DM, Fishbane S, Malyszko J, McCullough PA, Goldsmith D.

Am J Kidney Dis. 2015 Aug;66(2):196-205. doi: 10.1053/j.ajkd.2014.12.016. Epub 2015 Feb 26. Review.

33.

The effect of bicarbonate administration via continuous venovenous hemofiltration on acid-base parameters in ventilated patients.

Allegretti AS, Flythe JE, Benda V, Robinson ES, Charytan DM.

Biomed Res Int. 2015;2015:901590. doi: 10.1155/2015/901590. Epub 2015 Jan 8.

34.

Considerations and challenges in defining optimal iron utilization in hemodialysis.

Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S; Dialysis Advisory Group of the American Society of Nephrology.

J Am Soc Nephrol. 2015 Jun;26(6):1238-47. doi: 10.1681/ASN.2014090922. Epub 2014 Dec 26. Review.

35.

Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease.

Charytan DM, Padera R, Helfand AM, Zeisberg M, Xu X, Liu X, Himmelfarb J, Cinelli A, Kalluri R, Zeisberg EM.

Int J Cardiol. 2014 Sep;176(1):99-109. doi: 10.1016/j.ijcard.2014.06.062. Epub 2014 Jul 6.

36.

Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction.

Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B, Claggett B, Shah AM, Santos AB, Zile MR, Voors AA, McMurray JJ, Packer M, Bransford T, Lefkowitz M, Solomon SD; PARAMOUNT Investigators.

Eur Heart J. 2014 Dec 21;35(48):3442-51. doi: 10.1093/eurheartj/ehu254. Epub 2014 Jun 30.

37.

Do implantable defibrillators help patients with CKD?

Charytan DM, Reynolds MR.

Am J Kidney Dis. 2014 Jul;64(1):4-6. doi: 10.1053/j.ajkd.2014.04.007. No abstract available.

38.
39.

Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis.

Vardi M, Yeh RW, Herzog CA, Winkelmayer WC, Setoguchi S, Charytan DM.

Clin J Am Soc Nephrol. 2013 Dec;8(12):2213-20. doi: 10.2215/CJN.05130513. Epub 2013 Aug 22. Review.

40.

Risks of death and graft failure after surgical versus percutaneous coronary revascularization in renal transplant patients.

Charytan DM, Li S, Liu J, Qiu Y, Herzog CA.

J Am Heart Assoc. 2013 Feb 12;2(1):e003558. doi: 10.1161/JAHA.112.003558.

41.

Coronary vascular dysfunction and prognosis in patients with chronic kidney disease.

Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Dorbala S, Charytan DM, Blankstein R, Di Carli MF.

JACC Cardiovasc Imaging. 2012 Oct;5(10):1025-34. doi: 10.1016/j.jcmg.2012.06.007.

43.

Angiographic characteristics of coronary arterial segments progressing to myocardial infarction in patients with and without chronic kidney disease.

Charytan DM, Garg P, Varma M, Garshick MS, Jeon C, Mauri L.

Clin Exp Nephrol. 2013 Apr;17(2):232-9. doi: 10.1007/s10157-012-0682-7. Epub 2012 Aug 29.

PMID:
22926696
44.

You are what you eat: dietary salt intake and renin-angiotensin blockade in diabetic nephropathy.

Charytan DM, Forman JP.

Kidney Int. 2012 Aug;82(3):257-9. doi: 10.1038/ki.2012.148.

45.

CKD and coronary collateral supply in individuals undergoing coronary angiography after myocardial infarction.

Charytan DM, Stern NM, Mauri L.

Clin J Am Soc Nephrol. 2012 Jul;7(7):1079-86. doi: 10.2215/CJN.11171111. Epub 2012 Apr 19.

46.

Circulating endoglin concentration is not elevated in chronic kidney disease.

Charytan DM, Helfand AM, MacDonald BA, Cinelli A, Kalluri R, Zeisberg EM.

PLoS One. 2011;6(8):e23718. doi: 10.1371/journal.pone.0023718. Epub 2011 Aug 19.

47.

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E.

Kidney Int. 2011 Sep;80(6):572-86. doi: 10.1038/ki.2011.223. Epub 2011 Jul 13.

48.

Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States.

Charytan DM, Patrick AR, Liu J, Setoguchi S, Herzog CA, Brookhart MA, Winkelmayer WC.

Am J Kidney Dis. 2011 Sep;58(3):409-17. doi: 10.1053/j.ajkd.2011.03.026. Epub 2011 Jun 12. Erratum in: Am J Kidney Dis. 2012 Jun;59(6):895.

PMID:
21664735
49.

Albuminuria and cardiovascular risk: time for a new direction?

Charytan DM.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1235-7. doi: 10.2215/CJN.03630411. Epub 2011 May 19. No abstract available.

50.

Long-term clinical outcomes following drug-eluting or bare-metal stent placement in patients with severely reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry.

Charytan DM, Varma MR, Silbaugh TS, Lovett AF, Normand SL, Mauri L.

Am J Kidney Dis. 2011 Feb;57(2):202-11. doi: 10.1053/j.ajkd.2010.09.017. Epub 2010 Dec 24.

PMID:
21186075

Supplemental Content

Loading ...
Support Center